Ticker

MONTPELLIER, France--(BUSINESS WIRE)--Medincell (Euronext Paris: MEDCL) today announced the completion of non-dilutive financing transactions designed to strengthen its financing profile and align debt maturities with the Company's expected revenue growth trajectory and future cash flows. These cash flows are expected to be primarily driven by milestones and royalties from UZEDY®, which is already marketed, and from…

MedinCell S.A. (MDCLF) Q4 2026 Earnings Call Transcript

MONTPELLIER, France--(BUSINESS WIRE)--Medincell (Paris:MEDCL): Key Financial Highlights   Total revenues €24.3 million, including €9.3 million of UZEDY® royalties, confirming the evolution of the revenue model Operating result €(20.8) million, reflecting a planned increase in operating expenses to €45.0 million (+17% year-over-year) to support pipeline expansion and long-term value creation Liquidity position €84.8…

MONTPELLIER, France--(BUSINESS WIRE)--Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announced the hosting of live videoconference on Tuesday, June 16, 2026, to present its financial results for the fiscal year ending March 31, 2026. The results will be published earlier that day following the closing of the…

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announced that Christophe Douat, Chief Executive Officer, and Grace Kim, Chief Strategy Officer, U.S. Finance, will participate in the following leading U.S. investor conferences: Jefferies Annual NY Biotech…